Zacks Reiterates Neutral Rating for Aastrom Biosciences (ASTM)
Aastrom Biosciences (NASDAQ:ASTM)‘s stock had its “neutral” rating reaffirmed by Zacks in a note issued to investors on Wednesday, StockRatingsNetwork reports. They currently have a $5.00 price objective on the stock. Zacks‘ price target would indicate a potential upside of 27.88% from the company’s current price.
Zacks‘ analyst wrote, ” On Sunday, January 12, 2014, we arrived in San Francisco, CA for the annual JP Morgan Healthcare Conference, as well as the parallel Biotech showcase and OneMedForum Conferences. This was the eighth year in a row that we made the trip to San Francisco for these events, which are a must-attend for serious healthcare investors. During my three days in San Francisco, I conducted 25 one-on-one meetings with various managements of small and mid-cap biotechnology and specialty pharmaceutical companies. Below are some “notes” from our meeting with Aastrom Bio.”
A number of other firms have also recently commented on ASTM. Analysts at Thomson Reuters/Verus upgraded shares of Aastrom Biosciences from a “hold” rating to a “buy” rating in a research note to investors on Monday. Separately, analysts at MLV Capital cut their price target on shares of Aastrom Biosciences from $15.00 to $4.50 in a research note to investors on Wednesday, November 13th. They now have a “hold” rating on the stock. Finally, analysts at Maxim Group downgraded shares of Aastrom Biosciences from a “buy” rating to a “hold” rating in a research note to investors on Monday, October 28th. They now have a $10.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $3.78.
Aastrom Biosciences (NASDAQ:ASTM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($2.02) by $1.96.
Aastrom Biosciences, Inc (NASDAQ:ASTM) is a development stage company.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.